Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Nov 08,2022
Medicilon Appoints Dr. Renzong Xie DABT as Vice President of Toxicology Research
Recently, Shanghai Medicilon Inc. (Medicilon) appointed Dr. Renzong Xie as the Vice President of Toxicology Research Department.
More
Medicilon Appoints Dr. Renzong Xie DABT as Vice President of Toxicology Research
Oct 28,2022
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration
On October 19, AnDiCon Bio (AnDiCon) officially launched the phase II/III clinical study of ADC189 tablets, a new class 1 anti-influenza drug. The drug is expected to become the first class 1 innovative anti-influenza drug independently developed and approved for marketing in China.
More
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration
Oct 21,2022
Medicilon was awarded "Top 30 Listed Companies on the Science and Technology Innovation Board of China's Listed Companies"
Shanghai Medicilon Inc. was awarded the honorary title of "Top 30 Listed Companies on the Science and Technology Innovation Board".
More
Medicilon was awarded "Top 30 Listed Companies on the Science and Technology Innovation Board of China's Listed Companies"
Oct 19,2022
Medicilon appointed Dr. Rui Zhang as Senior VP of CMC
Recently, Shanghai Medicilon Inc. (hereinafter referred to as "Medicilon") appointed Dr. Rui Zhang as Senior Vice President of CMC.
More
Medicilon appointed Dr. Rui Zhang as Senior VP of CMC
Sep 29,2022
Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform
Recently, Ringene Biopharma, an innovative drug R&D company focusing on the development of drugs targeting RTK-RAS-MAPK signaling pathway, independently developed a new class of anti-tumor drugs, the irreversible pan-FGFR inhibitor RG002, which was approved clinical. The indications are advanced malignant tumors.
More
Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform
Sep 29,2022
Collaboration to empower gene therapy, OBiO Technology and Medicilon reach a strategic collaboration
On September 20, 2022, OBiO Technology (OBiO) and Shanghai Medicilon Inc. (Medicilon) held a signing ceremony of strategic collaboration in the field of gene and cell therapy services.
More
Collaboration to empower gene therapy, OBiO Technology and Medicilon reach a strategic collaboration
Sep 26,2022
The foundation stone laying of Medicilon's subsidiary Medicilon (Baoshan) was successfully held
On September 21, 2022, Medicilon (Baoshan) Inc's, a subsidiary of Shanghai Medicilon Inc, groundbreaking ceremony was held in North Shanghai Parmaceutical Industrial Park. This is another grand event following the opening of Medicilon (Hangzhou) on September 7.
More
The foundation stone laying of Medicilon's subsidiary Medicilon (Baoshan) was successfully held
Sep 14,2022
Medicilon Subsidiary Medicilon (Hangzhou) Inc. Grandly Opened!
On September 7, 2022, the opening ceremony of Medicilon (Hangzhou) Inc., a subsidiary of Shanghai Medicilon Inc., was held in Hangzhou.
More
Medicilon Subsidiary Medicilon (Hangzhou) Inc. Grandly Opened!
Sep 14,2022
Medicilon was selected as "2022 Shanghai Top 100 Emerging Industry Enterprises" and "2022 Shanghai Top 100 Growth Enterprises"
On the afternoon of August 30, 2022, Shanghai Enterprise Confederation, Shanghai Entrepreneurs Association, Shanghai Economic Organization Federation and Jiefang Daily jointly held a press conference for the 2022 Shanghai Top 100 Enterprises in the China Financial Information Center.
More
Medicilon was selected as "2022 Shanghai Top 100 Emerging Industry Enterprises" and "2022 Shanghai Top 100 Growth Enterprises"
Sep 01,2022
Medicilon has been approved as the first batch of Group Open Innovation (GOI) for large enterprises in Pudong in 2022
Shanghai Medicilon Inc. was invited to attend the GOI press conference. The Medicilian Academician Innovative Drug Maturation Center was selected as the 2022 Pudong Large Enterprise Open Innovation Center.
More
Medicilon has been approved as the first batch of Group Open Innovation (GOI) for large enterprises in Pudong in 2022
Aug 29,2022
Medicilon Assists | Cullgen's class 1 new drug TRK degrader CG001419 was approved for clinical use
On August 8, 2022, Cullgen Inc announced the approval of the IND application for a TRK degrader (CG001419) for the treatment of advanced solid tumors. CG001419 is the world's first in class TRK (neurotrophic factor receptor tyrosine kinase) protein degrader.
More
Medicilon Assists | Cullgen's class 1 new drug TRK degrader CG001419 was approved for clinical use
Aug 15,2022
Medicilon was awarded the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022"
Recently, the SMDC released the list of the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022". With its strong scientific and technological innovation strength, Shanghai Medicilon Inc. stands out from many outstanding enterprises and ranks among the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022".
More
Medicilon was awarded the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022"
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->